Urine Test for Kidney Protection in Diabetes Directs Treatment Choices

Urine Test for Kidney Protection in Diabetes Directs Treatment Selection

A simple urine test for kidney protection in diabetes can help doctors select which medications preserve renal function based on baseline protein levels. Researchers at Mass General Brigham led the analysis. They reviewed health records from 75,455 adults across the United States (U.S.).

The study evaluated participants over five years. All patients had moderate cardiovascular risk and used metformin as their baseline therapy. The results appeared in the British Medical Journal (BMJ).

Proteinuria Determines Renal Protection from Newer Diabetes Drugs

Patients who presented with protein in their urine experienced measurable renal protection from two newer drug classes. Glucagon-Like Peptide-1 (GLP-1) receptor agonists and Sodium-Glucose Transporter 2 (SGLT2) inhibitors lowered the rate of renal decline. The researchers compared these drugs directly against Dipeptidyl Peptidase-4 inhibitors (DPP4i).

This benefit appeared in 13,872 participants with baseline proteinuria. The pattern changed for participants with clear urine. For those patients, GLP-1 agonists and SGLT2 inhibitors showed little evidence of renal preservation.

Sulfonylureas Accelerated Kidney Decline in Lower-Risk Patients

Sulfonylureas were associated with faster declines in kidney function among patients who started without protein in their urine. This older drug class caused worse kidney outcomes than DPP4i in the low-risk cohort.

Doctors routinely prescribe sulfonylureas to lower blood sugar. The medication remains widely used due to low prescription costs. Yet the data links the drug class to accelerated renal decline in patients without proteinuria.

Target Trial Emulation Highlights Need for Individualized Prescribing

This investigation relied on a target trial emulation design using observational health data rather than a prospective randomized trial. Medical records provide broad real-world numbers but cannot fully eliminate unmeasured differences between patient groups. The researchers stressed that further trials must evaluate therapies for people without early kidney damage.

Prescriptions require individualized evaluation. Individuals managing blood sugar should talk to their clinician about using a urine test for kidney protection in diabetes before changing any prescribed medication.